

# SAHA Patient: IV vs ORAL (200 mg/dose)




FIG. 1

**Protocol 01-021 (ORAL SAHA) ARM A: SOLID TUMOR PATIENTS Cohort I (200 mg/dose)**




FIG. 2

### SAHA Patients: ORAL /Cohort I (200 mg/dose)




FIG. 3

**Protocol 01-021 (ORAL SAHA)**  
**ARM A: SOLID TUMOR PATIENTS**  
**Cohort I (200 mg/dose)**






FIG. 4

**Protocol 01-021 (ORAL SAHA)**  
**ARM A: SOLID TUMOR PATIENTS**  
**Cohort IIa (400 mg/dose)**  
**7-OS-400                    8-OS-400**



12/19/01



12/27/01

FIG. 5

## SAHA Patients: ORAL/Cohort II (400 mg/dose)




FIG. 6

**Protocol 01-021 (ORAL SAHA )**  
**ARM A: SOLID TUMOR PATIENTS**  
**Cohort IIa (400 mg/dose)**





FIG. 7

# SAHA Patients: ORAL/Cohort II (400 mg/dose)



## 12-OS-400

02/15/02




FIG. 8

# Oral 200 mg vs. 400 mg (Fasting)




Figure 9A

# Oral 200 mg vs. 400 mg (no-fasting)




Figure 9B

# IV 200 mg vs. 400 mg





Figure 9C

# Apparent Half-life of the Oral Dose




■=200 mg group (n=3-5); □=400 mg group (n=5-10)

3/4/2003

Figure 10

# AUC of the Oral Dose



■ =200 mg group (n=3-5); □ =400 mg group (n=5-10)

3/4/2003

Figure 11

# Bioavailability




Figure 12